Sanofi

This study tests a new vaccine (PCV21) that protects against 21 types of pneumococcal bacteria in healthy infants. About 2,360 babies will receive either the new vaccine or a current one at 2, 4, 6, and 12-15 months old. The main goal is to check for side effects and ensure the n…

This early-stage study tests a new vaccine (VXB-241) designed to protect against two respiratory viruses: RSV and HMPV. About 144 healthy adults, including those aged 60-83, will receive one dose of the vaccine at different strengths to check its safety and how well it boosts the…

This study tests a new vaccine designed to protect against four types of meningococcal bacteria that can cause serious infections like meningitis. Around 1,600 healthy children and teens aged 2 to 17 in China will receive either the new vaccine or a currently approved one. Resear…

This study tests a new 21-valent pneumococcal vaccine (PCV21) in about 1,092 healthy infants and toddlers to see if it is safe and helps their bodies build defenses against pneumococcal bacteria. The vaccine is given alongside routine childhood shots at ages 2, 4, and 11-15 month…

This study tests whether giving a new 21-valent pneumococcal vaccine after one, two, or three doses of a licensed 20-valent vaccine is safe and helps babies build strong immunity. About 580 healthy infants and toddlers will receive the vaccines at routine checkups. The goal is to…

This study tests a new vaccine designed to protect against the Omicron JN.1 variant of COVID-19. About 120 adults aged 65 and older, and teens and adults aged 12 to 64 with health conditions that raise their risk for severe COVID, will receive a single shot. Researchers will chec…

This study looks at the safety of the Tdap5 vaccine (Adacel) given to pregnant women after 27 weeks of pregnancy. Researchers will compare over 365,000 vaccinated and unvaccinated mothers and their babies to see if there are any differences in pregnancy outcomes like preterm birt…

This study tests a new mRNA vaccine designed to protect against a potential pandemic flu (H5N1). About 720 healthy adults aged 18 and older will receive either a high, medium, or low dose of the vaccine or a placebo. The goal is to see if the vaccine is safe and triggers a strong…

This study tests an experimental drug called amlitelimab in adults with celiac disease whose symptoms and gut damage persist despite a strict gluten-free diet. About 229 participants will receive either the drug or a placebo as a shot under the skin for up to 28 weeks. The goal i…

This study is testing a new drug called SAR447537 in adults with Alpha-1 antitrypsin deficiency (AATD) emphysema, a genetic condition that damages the lungs. The goal is to see if the drug is safe and helps control the disease over the long term. About 185 participants will recei…

This study looks at the long-term safety and effectiveness of a drug called amlitelimab for adults with moderate-to-severe asthma. Participants had already completed a previous amlitelimab study. The goal is to see if the drug remains safe and helps control asthma over up to 144 …

This study looks at the long-term safety and effectiveness of a drug called lunsekimig in adults with chronic sinusitis and nasal polyps that are not well controlled. Participants must have completed a previous lunsekimig study. The trial lasts about 56 weeks and measures side ef…

This study checks the long-term safety of the drug tolebrutinib in about 2,500 adults with multiple sclerosis who were in earlier trials. Participants take the drug for up to several years while doctors watch for side effects and track disability. The goal is to see if the drug r…

This study tests an experimental drug called BIVV020 in 48 adults who have received or will receive a kidney transplant. The goal is to see if it can prevent or treat antibody-mediated rejection, a common complication where the immune system attacks the new kidney. Participants r…

This study looks at the long-term safety of a gene therapy called SAR421869 for people with Usher syndrome type 1B, a rare condition that causes vision and hearing loss. Nine participants who received the treatment in a previous study are being followed for side effects and signs…

This study tests dupilumab, an injectable drug, in 69 adults with eosinophilic esophagitis (EoE), a condition that makes swallowing difficult due to inflammation and scarring in the esophagus. Participants receive either dupilumab or a placebo for 24 weeks, then all receive dupil…

This study tests whether dupilumab, an injectable drug, can slow the long-term decline in lung function for adults with moderate to severe asthma that is not well controlled by current treatments. About 1,300 participants will receive either dupilumab or a placebo for 3 years, al…

This early-stage study tests a new drug called SAR442257 in people with multiple myeloma or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. The main goals are to find a safe dose and check for side effects. About 47 adults will take part.

This study tests whether adding belumosudil to standard steroid treatment helps control chronic graft-versus-host disease (cGVHD), a complication after stem cell transplant. About 260 people aged 12 and older with newly diagnosed moderate to severe cGVHD will receive either the d…

This study tests the safety of a 14-day teplizumab treatment in 20 children under 8 who have stage 2 type 1 diabetes (early signs but no symptoms yet). The goal is to see if the drug is safe and how the body processes it, with the hope of delaying or preventing the disease from p…

This study tests whether a daily oral drug called venglustat can work as well as standard IV infusions (Cerezyme) for people with Gaucher disease type 3. About 43 adults and teens who have been stable on IV therapy for at least 3 years will take either the pill or continue IV inf…

This study tests whether a drug called amlitelimab can keep eczema under control for a full year in people aged 12 and older with moderate-to-severe atopic dermatitis. Participants who already responded to treatment in an earlier study will either continue receiving the drug ever…

This study looks at the long-term safety and effectiveness of the drug riliprubart for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and numbness. About 300 people who already completed a previous riliprubart study wil…

This study tests if a shot under the skin works as well as an IV infusion for the drug isatuximab, given with other medicines, for adults with multiple myeloma that has come back or not responded to treatment. About 531 participants will receive either the shot or the IV version.…

This study tests a one-time gene therapy (SAR444836) for adults with phenylketonuria (PKU), a genetic disorder causing high phenylalanine levels that require a strict diet. The treatment aims to safely lower these levels and allow patients to eat more freely. About 32 adults will…

This study follows about 200 people with hemophilia A who are taking a new medication called efanesoctocog alfa as part of their regular care. Researchers want to see how well it protects joints from bleeding over 5 years. No extra treatments are given—just observation of routine…

This study tests if dupilumab can help people with moderate to severe ulcerative colitis that has a specific immune marker (eosinophilic phenotype). About 68 adults will receive either dupilumab or a placebo for 52 weeks. The main goal is to see if symptoms and colon inflammation…

This study tests a monthly injection called fitusiran in 91 males aged 12 and older with severe hemophilia A or B, including those whose bodies have developed resistance to standard treatments. The goal is to see if fitusiran reduces the number of bleeding episodes compared to th…

This study tests an experimental drug called amlitelimab, given as a shot under the skin, for adults with severe alopecia areata—a condition causing major hair loss on the scalp. About 166 participants will receive either the drug or a placebo for 36 weeks to see if it helps hair…

This study tests whether adding the drug isatuximab to a standard three-drug regimen (bortezomib, lenalidomide, and dexamethasone) helps people with newly diagnosed multiple myeloma who cannot have a stem cell transplant live longer without their cancer worsening. About 475 parti…

This study tests an experimental drug called venglustat against usual treatments for Fabry disease in people who also have an enlarged heart. About 104 adults aged 18 to 65 will take part for 18 months, with heart and kidney function measured regularly. The goal is to see if veng…

This study tests the long-term safety and effectiveness of a new drug called amlitelimab for people aged 12 and older with moderate to severe atopic dermatitis (eczema). Participants receive the drug for up to 5 years and are monitored for side effects and how well the drug contr…

This study looks at the long-term safety of a drug called itepekimab for adults with chronic sinusitis and nasal polyps that are not well controlled. Participants who completed a previous itepekimab study will continue receiving the drug for another year. The goal is to see if it…

This study tests a new medicine called SAR441344 in people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 109 adults aged 18-70 will receive either the drug or a placebo for 24 weeks to see if it reduces lupus symptoms without causing serious …

This phase 3 study tests whether the drug frexalimab can delay disability worsening in people with nonrelapsing secondary progressive multiple sclerosis (nrSPMS). About 943 adults aged 18–60 are receiving either frexalimab or a placebo for up to 36 months. The main goal is to see…

This study tests whether adding the drug isatuximab to standard therapy (lenalidomide and dexamethasone) can delay the progression to active multiple myeloma in people with high-risk smoldering multiple myeloma. About 337 participants will receive either the combination or standa…

This study looks at the long-term safety of a drug called itepekimab for people with chronic obstructive pulmonary disease (COPD). About 700 adults who completed earlier itepekimab studies will receive the drug every 2 or 4 weeks for up to 52 weeks, followed by 20 weeks of monito…

This study tests a new way to give the drug isatuximab (as a shot under the skin) along with two other medicines (carfilzomib and dexamethasone) to adults whose multiple myeloma has come back or stopped responding to treatment. About 118 people who have had 1 to 3 prior treatment…

This study looks at how well dupilumab (Dupixent) works over 2 years in children aged 6 to 14 with moderate-to-severe atopic dermatitis (eczema). About 48 kids will receive the drug and researchers will measure skin barrier function and track side effects. The goal is to see if l…

This study tests an experimental drug called SAR443122 in 187 adults with moderate to severe ulcerative colitis. Participants receive either one of three doses of the drug or a placebo for up to 52 weeks. The goal is to see if the drug can reduce symptoms and inflammation, and to…

This study tests a pre-mixed injection that combines two diabetes drugs (insulin glargine and lixisenatide) in adults with type 2 diabetes whose blood sugar is not well controlled by pills or other injectables. About 105 participants will receive the combo treatment to see if it …

This study tests an experimental drug called SAR441344 in 129 adults with relapsing multiple sclerosis. The drug blocks a protein (CD40L) to reduce new active brain lesions seen on MRI. Participants receive either the drug or a placebo for several weeks. The goal is to see if the…

This large Phase 3 study compares a new investigational drug, frexalimab, to an approved daily pill (teriflunomide) in about 1655 adults with relapsing forms of multiple sclerosis. The main goal is to see if frexalimab reduces the number of relapses more effectively. Participants…

This study tests a new drug called brivekimig in people recently diagnosed with type 1 diabetes. The goal is to see if it can help preserve the body's ability to make some insulin, reducing the need for injected insulin. About 84 adults and adolescents will receive either the dru…

This study tests a new enzyme replacement therapy called avalglucosidase alfa in infants with Pompe disease, a rare genetic disorder that causes severe muscle weakness. The treatment is given by IV every other week for up to 4 years. The main goal is to see if more babies survive…

This study offers continued access to the drug isatuximab for adults with multiple myeloma who are still benefiting from it after finishing an earlier clinical trial. The main goal is to monitor long-term safety. About 70 participants will receive the treatment and be watched for…

This study looks at the long-term safety and effectiveness of amlitelimab, an injected drug for moderate to severe eczema (atopic dermatitis). It includes over 1,600 people who have already taken amlitelimab in earlier studies. Some participants will stop treatment temporarily to…

This study offers continued treatment with the oral drug rilzabrutinib to adults with chronic immune thrombocytopenia (ITP) who have already completed a long-term extension study in Japan. Only 4 participants who showed meaningful benefit and acceptable safety are eligible. The m…

This study looks at how safe and effective nirsevimab is at preventing severe RSV in babies and toddlers up to 24 months old. About 110 children will receive the medicine as part of their regular care. Researchers will track any side effects and how many children get sick with RS…

This study follows 100 adults with prurigo nodularis, a chronic itchy skin condition, who are already prescribed dupilumab by their doctor. Researchers will track why patients start or stop the drug, how they use it, and whether it reduces hospital visits. The goal is to see how …

This study tests if a drug called dupilumab can reduce severe itching in adults with lichen simplex chronicus, a skin condition that causes intense, persistent itch. About 138 participants will receive either dupilumab or a placebo injection for 24 weeks. The main goal is to see …

This study tests a drug called itepekimab for adults with chronic sinusitis and nasal polyps that are not well controlled. About 231 participants will receive either the drug or a placebo for 52 weeks, along with standard nasal spray. The goal is to see if itepekimab can shrink p…

This study tests whether the drug venglustat can reduce nerve pain in the arms and legs, and belly pain, in people with Fabry disease. About 122 participants aged 16 and older who have not had Fabry treatment for at least 6 months will take either venglustat or a placebo for 12 m…

This study tests if dupilumab injections can reduce severe itching in adults with lichen simplex chronicus, a condition causing thick, itchy skin patches. About 142 participants will receive either dupilumab or a placebo for 24 weeks. The main goal is to see if more people get me…

This study tests an experimental drug called itepekimab in 60 adults with chronic sinusitis that doesn't improve with standard sprays. The goal is to see if it reduces sinus swelling and symptoms like stuffiness, runny nose, and facial pain. Participants receive either the drug o…

This study follows 143 children aged 6 months to 11 years with severe atopic dermatitis (eczema) in Spain who are starting treatment with dupilumab. Researchers will observe how the drug is used in real-world clinics, its effectiveness, and any side effects over two years. No ext…

This study tests whether a single dose of balinatunfib affects the heart's electrical activity in 48 healthy adults aged 18 to 55. Researchers measure changes in heart rhythm over time using an ECG. The goal is to ensure the drug is safe for the heart before moving to larger tria…

This study follows 376 asthma patients aged 12 and older who are starting Dupixent in everyday medical practice. Researchers will collect information on patients' medical history, how they use the drug, and how well it controls their asthma. The goal is to understand real-world e…

This study looks at whether healthcare professionals in Saudi Arabia are aware of and follow safety measures for the drug Leflunomide (Arava), used for rheumatoid and psoriatic arthritis. Researchers will survey about 3,500 doctors and pharmacists to see if they received and read…

This study follows 150 adults in France with severe chronic sinusitis and nasal polyps who are taking dupilumab (Dupixent). Researchers will describe patient characteristics, past treatments, and how symptoms change over two years. The goal is to understand real-world use and saf…